Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05495152
• Other study ID #: HCHTOG2203
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 1, 2022
• Est. completion date: August 31, 2028

Study information

• Verified date: August 2022
• Source: Henan Cancer Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2 N0 patients with incidental pathologic lymph node metastasis following initial surgery. To investigate the outcomes of adjuvant Sintilimab in patients with locally advanced ESCC, we initiated this randomized controlled trial (RCT).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 219
• Est. completion date: August 31, 2028
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Histologically proven squamous cell carcinoma.

2. Tumours are located in the thoracic oesophagus.

3. Age is between 18 years and 70 years.

4. ECOG performance status of 0 or 1.

5. Patients with resectable cT1-4aN+M0 or T3-4aN0M0 disease and residue disease is found after neoadjuvant chemotherapy plus surgery or cT1-2N0M0 and pathologically proven T1-2N+M0 after upfront surgery.

6. No metastatic cervical lymph nodes.

7. R0 resection is achieved by the minimally invasive esophagectomy (MIE) or open McKeown approach with total two-field lymph nodes dissection or three-field lymph nodes dissection.

8. No prior therapy was administered against other cancers.

9. Adequate bone marrow function: white blood cell count = 4×109/L; absolute neutrophil count (ANC) = 1.5×109/l; platelets = 100×109/L; haemoglobin = 9 g/dl.

10. Adequate liver function: serum bilirubin = 1.5 × upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) = 2.0 × ULN (ULN as per institutional standard).

11. Adequate renal function: glomerular filtration rate = 60 ml/min calculated using the Cockcroft-Gault formula.

12. Normal thyroid function.

13. Written consent is obtained.

Exclusion Criteria:

1. Patients receive neoadjuvant chemoradiation therapy.

2. Patients with pathological complete response (pCR).

3. No. of lymph node dissection < 15.

4. Patients with clinical stages T1-2N+M0 and receive upfront surgery.

5. Patients with unresectable disease (bulky metastatic lymph nodes or T4b) and receive induction chemotherapy.

6. Patients requiring systemic steroid medication.

7. Patients with severe postoperative complications and not suitable for adjuvant therapy.

8. Synchronous or metachronous (within 5 years) double cancers.

9. Patients ever received immunotherapy.

10. Active infection requiring systemic therapy.

11. Patients ever received organ transplant or allogenic haemopoietic stem cell transplantation.

12. Patients with human immunodeficiency virus (HIV) infection.

13. Psychiatric disease.

14. Pregnant or lactating women or women of childbearing potential.

15. Hypersensitivity for Sintilimab.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• Sintilimab
Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.

Locations

Country	Name	City	State
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease-free Survival (DFS)	DFS is defined as the time from the date of randomization to the date of first recurrence (local, regional or distant) or death.	DFS is defined as the time from the date of randomization to the date of first recurrence (local, regional or distant) or death , assessed up to 36 months